• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin.

作者信息

Henderson S J, Lindup W E

机构信息

Department of Pharmacology and Therapeutics, University of Liverpool, U.K.

出版信息

Biochem Pharmacol. 1990 Dec 1;40(11):2543-8. doi: 10.1016/0006-2952(90)90097-5.

DOI:10.1016/0006-2952(90)90097-5
PMID:2268372
Abstract

The furan dicarboxylic acid 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (5-propyl FPA) accumulates in uraemic plasma and is a potent inhibitor of the binding of other anionic ligands to albumin. The interaction of 5-propyl FPA with human albumin has been investigated by equilibrium dialysis at 37 degrees and pH 7.4. Analysis of the binding data on the basis of a two-site model gave binding parameters of n1 = 0.6 and K1 = 4.8 x 10(6) M-1 for the primary binding site. 5-Propyl FPA binding was observed to decrease as the pH was raised from 6.4 to 8.3 which emphasizes the need for pH control of whole plasma or serum. Temperature, however, had little effect on binding as assessed by equilibrium dialysis at 10 degrees, 25 degrees and 37 degrees. The high affinity of 5-propyl FPA for albumin explains its retention in uraemic plasma, its potency as a binding inhibitor and points to active tubular secretion as the mechanism by which it is normally excreted by the kidney.

摘要

相似文献

1
Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin.
Biochem Pharmacol. 1990 Dec 1;40(11):2543-8. doi: 10.1016/0006-2952(90)90097-5.
2
Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant.
Nephrol Dial Transplant. 1996 May;11(5):803-7. doi: 10.1093/oxfordjournals.ndt.a027402.
3
Synthesis and physicochemical properties of the furan dicarboxylic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia.
J Pharm Pharmacol. 1996 Jun;48(6):635-40. doi: 10.1111/j.2042-7158.1996.tb05987.x.
4
Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia.
J Pharmacol Exp Ther. 1992 Oct;263(1):54-60.
5
Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia.
Kidney Int. 1996 Mar;49(3):634-8. doi: 10.1038/ki.1996.91.
6
Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin.两种二羧酸内源性物质,胆红素和一种尿毒症毒素3-羧基-4-甲基-5-丙基-2-呋喃丙酸,对人血清白蛋白的相互作用。
Pharm Res. 1999 Jun;16(6):916-23. doi: 10.1023/a:1018842506896.
7
Characterization of binding site of uremic toxins on human serum albumin.尿毒症毒素与人血清白蛋白结合位点的表征
Biol Pharm Bull. 1995 Dec;18(12):1755-61. doi: 10.1248/bpb.18.1755.
8
Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?
Nephron. 1996;73(2):169-73. doi: 10.1159/000189035.
9
Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.尿毒症血清中阴离子药物对与白蛋白结合的内源性配体的置换作用。
Ther Drug Monit. 1988;10(3):261-4. doi: 10.1097/00007691-198803000-00003.
10
A major inhibitor of phenytoin binding to serum protein in uremia.尿毒症中苯妥英与血清蛋白结合的主要抑制剂。
Nephron. 1988;48(4):310-4. doi: 10.1159/000184949.

引用本文的文献

1
Detailing Protein-Bound Uremic Toxin Interaction Mechanisms with Human Serum Albumin in the Pursuit of Designing Competitive Binders.解析蛋白结合尿毒症毒素与人体血清白蛋白相互作用机制,设计竞争结合物。
Int J Mol Sci. 2023 Apr 18;24(8):7452. doi: 10.3390/ijms24087452.
2
Renal insufficiency and cancer treatments.肾功能不全与癌症治疗。
ESMO Open. 2016 Aug 18;1(4):e000091. doi: 10.1136/esmoopen-2016-000091. eCollection 2016.
3
The role of the protein-binding on the mode of drug action as well the interactions with other drugs.
蛋白质结合在药物作用模式以及与其他药物相互作用方面的作用。
Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):225-30. doi: 10.1007/BF03190876.
4
Furan fatty acids: occurrence, synthesis, and reactions. Are furan fatty acids responsible for the cardioprotective effects of a fish diet?呋喃脂肪酸:存在、合成及反应。呋喃脂肪酸是否对鱼类饮食的心脏保护作用负责?
Lipids. 2005 Aug;40(8):755-71. doi: 10.1007/s11745-005-1438-5.
5
The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.衰老对健康受试者及肾功能损害患者血浆白蛋白以及地西泮、水杨酸和洋地黄毒苷血浆蛋白结合的影响。
Br J Clin Pharmacol. 1992 Mar;33(3):299-304. doi: 10.1111/j.1365-2125.1992.tb04039.x.
6
Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.药物血浆和组织结合的测定方法。药代动力学后果。
Clin Pharmacokinet. 1992 Dec;23(6):449-68. doi: 10.2165/00003088-199223060-00005.